Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime-tazobactam versus meropenem for complicated urinary tract infection or acute pyelonephritis
2017-005117-31Phase 3Suspended
- Sponsor
- Wockhardt
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefepime + tazobactam, meropenem and ciprofloxacin in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Wockhardt. Primary endpoints: Overall success at Day 5 in mMITT population and Overall success at test-of-cure in mMITT population. Started Jun 2018; status: suspended.
02
Drugs
cefepime + tazobactammeropenemciprofloxacin
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2017-005117-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005117-31.